Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical announces a revised proposal for the privatization of Henlius, allowing shareholders to choose between a cash payment or shares in newly established rollover entities. This move, aiming to withdraw Henlius from public listing, offers a cash alternative of HK$24.60 per share or an equivalent share exchange, reflecting the company’s strategic consolidation efforts.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
